日本无限资源_福禄影院午夜伦_美国av毛片_亚洲自拍在线观看_激情亚洲一区国产精品_999久久久久

Higher doses of radiation don't improve survival in prostate cancer: study

Source: Xinhua| 2018-03-16 06:07:14|Editor: yan
Video PlayerClose

CHICAGO, March 15 (Xinhua) -- Compared with standard radiation treatment, higher doses of radiation do not improve survival for many patients with prostate cancer, a study led by researchers at Washington University School of Medicine in St. Louis shows.

The study included about 1,500 patients with intermediate-risk prostate cancer that most patients fall into. To be classified in this risk category, patients generally have PSA scores of 10-20 ng/ml and a Gleason score of seven.

Both treatment groups received external beam radiation. The standard group received a radiation dose of 70.2 gray delivered over 39 treatment visits. The investigational group received increasing doses up to 79.2 gray delivered over 44 visits. A gray is the standard measure of radiation a material has absorbed.

Of the 748 men receiving standard treatment, 75 percent were still alive after eight years of follow-up. Of the 751 men receiving the dose-escalation treatment, 76 percent were alive at the eight-year mark, a difference that is not statistically significant.

Over the course of the study, 51 patients died of prostate cancer, which is 3.4 percent of all patients enrolled. At the eight-year mark, the death rate due to prostate cancer for patients receiving standard treatment was four percent compared with two percent for patients receiving the escalating dose. These rates also were not statistically different.

While there was no difference in overall survival numbers, Jeff M. Michalski, first author and professor of radiation oncology of Washington University, pointed out some differences in side effects and in whether further treatment was needed later.

Patients in the standard dose group were more likely to undergo further therapies to control tumors that had grown larger or that had spread to another site in the body. While patients in the escalating dose group experienced more side effects, such as urinary irritation or rectal bleeding, sometimes years after treatment.

During the 10 years it took to enroll enough patients in the trial, at least six new therapies were approved for recurrent or metastatic prostate cancer, and these therapies have been shown to improve survival.

"If there is a difference between standard and escalating doses, it's hard to show it when the patients who later develop recurrent cancer can have their lives extended through the use of additional therapies," said Michalski.

The study, the first that is large enough to examine whether these improved measurements translate into longer survival for patients, is published Thursday in JAMA Oncology.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011105521370422301
主站蜘蛛池模板: 国产高清美女一级a毛片久久w | 色综合视频一区二区三区高清 | 歪歪爽蜜臀AV久久精品人人槡 | 91精产国品一二三区在线观看 | 村女艳史理伦一及毛片 | 狠狠色噜噜狠 | 无码毛片一区二区本码视频 | 中国一级伦理片 | 91看片免费在线观看 | 国产精品久久久久久日本 | 国产性一乱一性一伧一色 | 一本色道久久88亚洲精品综合 | 欧美综合在线观看视频 | 久久综合九色 | 美女h片| 中日韩欧美中文字幕 | 欧美激情高清 | 欧美成人久久久 | 国产片XXXXA片国语对白 | av在线视屏 | 麻豆神马91 | 色欲AV亚洲情无码AV蜜桃 | 日产精品久久久久久久蜜臀 | 久久人人爽人人爽人人片av软件 | 亚洲精品国产综合99久久夜夜嗨 | 自拍偷拍亚洲欧美 | 国产丰满老熟女一区二区三区 | 日韩大胆视频 | 国产AV无码专区亚洲AV潘金链 | 国产亚洲影视在线视频播放 | 亚洲色成人一区二区三区小说 | 18禁无遮挡啪啪无码网站 | 国产91精品高清一区二区三区 | 免费看av在线网站网址 | 国产一区二区怡红院 | 亚洲精品乱码久久久久久久 | 中文字幕在线播放一区 | 国产成年无码V片在线 | 久操网在线 | 免费一级黄色大片 | 久久久视频在线 |